We are live on ! Find out more
REPL icon

Replimune Group

77 hedge funds and large institutions have $631M invested in Replimune Group in 2020 Q2 according to their latest regulatory filings, with 25 funds opening new positions, 36 increasing their positions, 13 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

525% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 4

186% more capital invested

Capital invested by funds: $221M → $631M (+$410M)

177% more repeat investments, than reductions

Existing positions increased: 36 | Existing positions reduced: 13

100% more funds holding in top 10

Funds holding in top 10: 24 (+2)

38% more funds holding

Funds holding: 5677 (+21)

8.62% more ownership

Funds ownership: 60.5%69.12% (+8.6%)

Holders
77
Holders Change
+21
Holders Change %
+37.5%
% of All Funds
1.58%
Holding in Top 10
4
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+100%
% of All Funds
0.08%
New
25
Increased
36
Reduced
13
Closed
4
Calls
Puts
Net Calls
Net Calls Change

REPL Hedge Fund Activity: Q2 2020 in Review

77 of the 4,888 institutional investors tracked by Wall St. Rank reported a position in Replimune Group (REPL) for Q2 2020, worth a combined $631M — up 186% from $221M a quarter earlier.

Buyers outnumbered sellers: 25 funds opened new REPL positions and 4 closed out — a net gain of 21 holders — while 36 added to existing stakes and 13 trimmed.

The largest buyer was Victory Capital Management, adding an estimated $11.9M. The largest seller was Bain Capital Life Sciences Investors, cutting an estimated $12M.

  • 77 institutional investors held Replimune Group (REPL) as of Q2 2020, up from 56 in Q1 2020.
  • Funds reported $631M of Replimune Group stock for Q2 2020, up 186% quarter-over-quarter.
  • 25 funds opened new Replimune Group positions in Q2 2020 and 4 closed out, a net change of +21 holders.
  • The largest Replimune Group buyer in Q2 2020 was Victory Capital Management, an estimated $11.9M added.
  • The largest Replimune Group seller in Q2 2020 was Bain Capital Life Sciences Investors, an estimated $12M sold.

Based on aggregated 13F filings for Q2 2020.